Peptide Drugs Become the Largest New Drug Modality, Weight Loss Market Drives High Growth

Overview

This report focuses on the rapidly growing obesity drug market and explores the major opportunities and challenges faced by peptide drugs, which serve as its core carrier, in the production and manufacturing环节. The report points out that peptides have become the leading new drug modality in terms of scale and growth rate, but their mainstream production process, solid-phase peptide synthesis (SPPS), has significant issues such as high solvent consumption, large waste generation, and high costs, characterized as 'dirty, chaotic, and poor.' To address these bottlenecks, leading contract research and manufacturing organizations (CDMOs) are actively adopting innovative technologies, such as continuous chromatography purification (MCSGP), tag-assisted synthesis (TAPS), and process analytical technology (PAT), to reduce process mass intensity (PMI), improve production efficiency, and enhance sustainability. The report believes that companies successfully overcoming manufacturing challenges will gain an advantage in this high-growth market.

Core views

The core view of the report is that despite the promising prospects of the peptide drug market, the core bottleneck for large-scale commercialization lies in the manufacturing环节. The explosive growth of the obesity drug market has propelled peptides to the forefront of new drug modalities, with global related expenditures projected to grow at a compound annual rate of over 20% for the next five years, adding more than $50 billion in incremental value. However, this growth also brings significant manufacturing pressures. Currently, major GLP-1 drugs like semaglutide and tirzepatide, along with blockbuster drugs such as octreotide and lanreotide, all rely on chemical synthesis or hybrid routes for production. Industry analysis shows that producing one kilogram of such peptide active pharmaceutical ingredients (APIs) may require up to 16,000 kilograms of chemicals, with solvents and reagents being the main components, not only increasing costs (COGS) but also generating substantial hazardous waste, making it one of the least environmentally friendly drug modalities. Therefore, the report emphasizes that peptide manufacturing faces three severe challenges: first, high process mass intensity (PMI) and solvent consumption threaten the sustainability and profitability of production; second, batch purification and complex multi-step workflows limit effective capacity and increase the risk of batch failures; third, increasingly stringent ESG and regulatory requirements put enterprises relying on traditional high-solvent platforms at risk of losing market share and client contracts. In this context, technological innovation becomes the key to breaking through these challenges. For example, Bachem was the first to commercialize multi-column continuous countercurrent solvent gradient purification (MCSGP) technology, reducing solvent consumption by about 30% and total material usage by 70% compared to traditional batch purification, shortening purification time from five days to one day, greatly improving equipment and quality inspection resource utilization. Meanwhile, WuXi Apptec announced that its latest data show it has reduced PMI by more than three times relative to industry benchmarks, lowering costs by reducing solvent and reagent usage and alleviating environmental burdens through solvent recovery. Additionally, companies like Asymchem are also adopting greener synthetic routes, real-time process analytical technology, and continuous flow reactors to accelerate process performance qualification (PPQ) processes and achieve faster project delivery.

Analysis framework

The report begins with macro-market trends, citing IQVIA data to establish the leading position of obesity drugs and their core carrier—peptides—in the future pharmaceutical market, thus shifting attention to the supply chain end, i.e., the manufacturing环节. Next, the report thoroughly analyzes the technical details of the current mainstream production processes (particularly SPPS), clearly identifying its essential characteristics of high solvent consumption and high PMI, quantifying them (e.g., 14 tons of solvent per kilogram vs. 0.3 tons per kilogram for small molecule drugs), making the issues specific and visual. After identifying the three pain points of 'high cost, low efficiency, and non-environmental friendliness,' the report's analytical approach shifts to solutions, examining how leading companies (primarily CDMOs) address these challenges through technological innovation. The report selects Bachem (MCSGP) and WuXi Apptec (PMI optimization) as typical cases, elaborately explaining the working principles of new technologies, the specific benefits they bring (e.g., percentage of solvent savings, days saved in time, capacity improvement data), and supporting these with charts to build a complete logical chain of 'market demand -> manufacturing bottlenecks -> technological innovation -> efficiency and sustainability improvements.'

Methodology notes

• Industry/Industrial Analysis FrameworkSupply and Demand Framework

  The core focus of this industry is on supply

  The main analytical thread of the report starts from strong market demand (obesity treatment) and ultimately lands on the bottlenecks and breakthroughs in the supply side (manufacturing capability). It emphasizes that even if demand is robust, if the supply side cannot efficiently and cost-effectively meet it, the full potential of the entire market cannot be fully realized. Therefore, when evaluating investment opportunities in this area, attention should not only be paid to the R&D pipelines of downstream pharmaceutical companies but also deeply studied upstream CDMO manufacturing capabilities and technical barriers.

• Industry/Industrial Analysis FrameworkCost curve analysis

  PMI is the core indicator for measuring the cost efficiency of peptide manufacturing

  Process mass intensity (PMI) is used as a key cost efficiency indicator. It represents the total mass of all input materials required to produce a unit product. A lower PMI directly implies less raw material consumption, lower procurement costs, fewer waste disposal costs, and higher capital utilization efficiency. The report visually demonstrates the significant cost advantages brought by technological progress by comparing the industry average PMI (~13,000) with the optimized PMI of leading companies (e.g., WuXi Apptec, reduced by more than three times).

• Industry/Industrial Analysis FrameworkSubstitution Effect Analysis

  Competition and substitution among different synthetic technology routes

  The report compares various peptide synthesis methods (SPPS, LPPS, Hybrid, TAPS), analyzing their target molecules, technical differences, and commercial applications. This reflects the logic of substitution effect analysis: different technology routes are potential substitutes for each other. For instance, although SPPS is currently the standard, new technologies like TAPS, which can reduce solvent waste, are gaining application in certain areas, thereby exerting substitution pressure on traditional methods.

• Macroeconomic frameworkCredit/debt cycle

  ESG factors affect corporate financing costs

  The report mentions that pharmaceutical companies face pressure from scope 3 emissions. Choosing CDMOs with quantified PMI emission reductions and solvent recovery capabilities helps improve their sustainable development narrative. The underlying logic here is that in the current financial environment emphasizing ESG, good sustainability performance can translate into stronger investor confidence and lower financing costs (i.e., better credit ratings or bond issuance conditions), whereas the opposite could result in higher capital costs.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi Apptec

  Benefits from its leading position and technological breakthroughs in the peptide CMO field.

  Strengths

  Operates over 100,000 liters of SPPS capacity, announced PMI reduction exceeding three times, optimizing costs and ESG performance through solvent reduction and recycling.

• Bachem

  As a leader in peptide CDMO, consolidates its premium manufacturing position through technological innovation.

  Strengths

  First to commercialize MCSGP technology, achieving a 30% reduction in solvent consumption, 70% reduction in material usage, and shortening purification time from five days to one day.

• Asymchem

  Benefits from the overall expansion and technological upgrading trend in the peptide CDMO industry.

  Strengths

  Adopts greener synthetic routes, real-time process analytical technology (PAT), and tag-assisted synthesis (TAPS), achieving faster PPQ cycles (e.g., 12-month case).

Key data

• Annual Compound Growth Rate of Global Obesity Drug Expendituremid-20s%Expected compound growth from 2025 to 2029, adding over $50 billion in new expenditures.
• Solvent Consumption for Producing 1kg of GLP-1 Agonist Peptide14 tEquivalent to 14,000 kilograms, highlighting the massive resource consumption in the manufacturing process.
• Solvent Consumption for Producing 1kg of Typical Small Molecule Drug0.3 tContrasts sharply with peptides, highlighting the unique challenges of peptide manufacturing.
• WuXi Apptec's PMI Optimization AchievementsReduced by more than 3XCompared to industry benchmarks, significantly reduced the material footprint in the production process.
• MCSGP Technology Purification Time1 dayCompared to approximately 5 days for traditional batch purification, showing a significant improvement in efficiency.

Impact & implications

The report believes that technological innovations in peptide manufacturing will reshape the industry landscape. CDMOs that can first master and scale up efficient, green manufacturing processes will gain significant competitive advantages. This is not only reflected in lower costs and higher profit margins but more importantly, it meets the increasingly strict ESG requirements of major pharmaceutical companies, thereby winning more stable and sticky customer contracts. For downstream innovator pharmaceutical companies, ensuring stable, high-quality, and sustainable API supply is crucial for the successful launch of their products and maintaining market positions. Therefore, the value center of the entire industry chain is tilting towards suppliers with strong manufacturing capabilities and innovation. Companies that fail to keep pace with technological changes may gradually lose market share due to cost disadvantages and environmental compliance risks.

Risks

• If CDMOs cannot effectively reduce solvent and raw material consumption per kilogram of product, the continuously increasing production volume will amplify cost and environmental responsibility risks.
• Batch purification and complex multi-step workflows may lead to batch failures, constraining revenue growth and creating supply risks.
• Increasing expectations for waste minimization and impurity control under ESG and regulatory requirements mean that companies continuing to use traditional high-solvent platforms may face risks of market share loss, higher capital expenditures, or unstable client contracts.

What to watch

• Continuous progress and actual data disclosure by leading CDMOs (e.g., WuXi Apptec, Bachem, Asymchem) in reducing PMI and solvent consumption.
• The promotion speed and acceptance level of innovative manufacturing technologies like MCSGP and TAPS within the industry.
• Changes in the weight given to ESG performance and sustainability metrics when large pharmaceutical companies select CDMO partners.